<?xml version='1.0' encoding='utf-8'?>
<document id="20208392"><sentence text="Species differences in mechanism-based inactivation of CYP3A in humans, rats and mice." /><sentence text="Mechanism-based inactivation (MBI) of cytochrome P450 3A (CYP3A) often causes serious drug-drug interactions" /><sentence text=" To examine species differences in MBI of CYP3A between humans and rodents, we compared MBI potencies of five representative CYP3A inhibitors in human, rat and mouse liver microsomes" /><sentence text=" Among the inhibitors studied, erythromycin and clarithromycin exhibited markedly weaker MBI effects on CYP3A activity in rat and mouse liver microsomes compared to human liver microsomes"><entity charOffset="31-43" id="DDI-PubMed.20208392.s4.e0" text="erythromycin" /><entity charOffset="48-62" id="DDI-PubMed.20208392.s4.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.20208392.s4.e0" e2="DDI-PubMed.20208392.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20208392.s4.e0" e2="DDI-PubMed.20208392.s4.e1" /></sentence><sentence text=" Results of spectroscopic experiments showed that erythromycin and clarithromycin form a metabolic intermediate complex with human liver microsomes but not with rat or mouse liver microsomes"><entity charOffset="50-62" id="DDI-PubMed.20208392.s5.e0" text="erythromycin" /><entity charOffset="67-81" id="DDI-PubMed.20208392.s5.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.20208392.s5.e0" e2="DDI-PubMed.20208392.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20208392.s5.e0" e2="DDI-PubMed.20208392.s5.e1" /></sentence><sentence text=" In contrast, troleandomycin, diltiazem and nicardipine form a metabolic intermediate complex with rat and mouse liver microsomes, although some differences in MBI potency among species were observed"><entity charOffset="14-28" id="DDI-PubMed.20208392.s6.e0" text="troleandomycin" /><entity charOffset="30-39" id="DDI-PubMed.20208392.s6.e1" text="diltiazem" /><entity charOffset="44-55" id="DDI-PubMed.20208392.s6.e2" text="nicardipine" /><pair ddi="false" e1="DDI-PubMed.20208392.s6.e0" e2="DDI-PubMed.20208392.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20208392.s6.e0" e2="DDI-PubMed.20208392.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20208392.s6.e0" e2="DDI-PubMed.20208392.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20208392.s6.e1" e2="DDI-PubMed.20208392.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20208392.s6.e1" e2="DDI-PubMed.20208392.s6.e2" /></sentence><sentence text=" Parameters for MBI potency (k(inact)/K(I) ratio) and reversible inhibition (IC(50)) were negatively correlated (r=-0" /><sentence text="820, p=0" /><sentence text="0003), suggesting that the different affinities of CYP3A inhibitor for CYP3A may partly contribute to the different MBI potencies of inhibitor among species" /><sentence text=" Taken together, the results suggest that there are species differences in MBI of CYP3A in humans, rats and mice, which should be considered when rodents are used as in vivo models for MBI-mediated drug-drug interaction study" /><sentence text="" /></document>